SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-009220
Filing Date
2024-03-07
Accepted
2024-03-07 16:30:39
Documents
17
Period of Report
2024-03-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44533
2 ex2-1.htm EX-2.1 53925
3 ex3-1.htm EX-3.1 591184
4 ex3-2.htm EX-3.2 286987
  Complete submission text file 0001493152-24-009220.txt   1325511

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE mymd-20240304.xsd EX-101.SCH 3003
6 XBRL LABEL FILE mymd-20240304_lab.xml EX-101.LAB 34240
7 XBRL PRESENTATION FILE mymd-20240304_pre.xml EX-101.PRE 22351
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3739
Mailing Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205
Business Address 855 N. WOLFE STREET SUITE 601 BALTIMORE MD 21205 856-848-8698
MyMD Pharmaceuticals, Inc. (Filer) CIK: 0001321834 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36268 | Film No.: 24730607
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)